TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: recurrent atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Ratio (GMR) of AUC(0-72 hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric Mean Ratio (GMR) of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decisional conflict total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Effective Decision Making subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medically attended wheezing
Endpoint domain: Adverse events/effects
Primary endpoint: laboratory-confirmed influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in near misses
Endpoint domain: Adverse events/effects
Primary endpoint: short-term post-treatment urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: variability of hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ki-67 index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL) function scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nutritional intake (energy and protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average RPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic evidence of tubal closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fugl-Meyer score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Brunnstrom motor function rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: modified Ashworth spasm rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Hemoglobin A1c goal achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL cholesterol goal achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Restraint use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall success of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for insulin to achieve glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: proportion of days abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectacle independency for distance vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected distance visual acuity of 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chances for survival
Endpoint domain: Mortality/survival
Primary endpoint: Independent functional state (mRS ≤2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extrapulmonary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary excretion of LTE(4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reversal of angiographically confirmed vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean severe exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 30-day re-bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure to control bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thirst
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hunger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: drinks per day at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of partners notified
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of clinically significant bleeding events (CSBEs) per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD28 and CD38 frequencies in peripheral blood lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearing of MC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final alveolar bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shrinkage rate of the grafted area volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC-CFUs levels before PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC-CFUs levels after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative urinary catheter‐induced discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regression of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteal phase serum levels of inhibin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Luteal phase serum levels of pro-alphaC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum mean percent IOP decrease from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: algometric assessment improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged abstinence at six months
Endpoint domain: Mortality/survival
Primary endpoint: Decrease of hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of the procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in total score on the teacher-rated ADHD Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement scale rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in tic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative body core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post anesthesia Aldrete Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with post-thrombotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding events within 10 days
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate-to-severe post-thrombotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma-free tryptophan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neocortical activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Attentional-set shifting task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual-search task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improved preparedness to care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Balance as measured by the Sensory Organization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substantial vertigo control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence criteria for AUC and C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic parameters for IGF1, IGF-binding protein 3, and non-esterified fatty acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of efficacy failure
Endpoint domain: Mortality/survival
Primary endpoint: Active range of wrist extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum velocity of wrist extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: herpes zoster (HZ)
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal thermal comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of maternal shivering
Endpoint domain: Adverse events/effects
Primary endpoint: impaired organ function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in smoking frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cigarettes smoked per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5XSTS test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSFS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12 PCS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean maximum plasma concentrations (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the plasma concentration‐time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harmonic mean terminal elimination half‐life (t((1/2)))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1, 3, 5 and 10-year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Expression levels of AT2-R gene transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMD percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of the cross‐sectional area of median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-vigorous physical activity participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum inspiratory and expiratory pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: readmissions or death
Endpoint domain: Mortality/survival
Primary endpoint: HAQ score ≥ 1 after 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Success rates of procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity associated with tongue base suspension
Endpoint domain: Adverse events/effects
Primary endpoint: self-report anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recovery time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: behavioral indices of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient care competencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical knowledge competencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PO-SCORAD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in stroke‐related impairment (Canadian Neurological scale score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alpha band mean frequency shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: alpha band median frequency decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: beta band power fraction decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of women experiencing unacceptable levels of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction after surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of reducible acute dislocations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hypoglycemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with insulin delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IL-4 and IL-13 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disability scores (Oswestry)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Streptococcus mutans count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: apparent clearance of dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: withdrawals for toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: erythrocyte sedimentation rate improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C reactive protein improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive subscale scores in the Clinical Global Impression‐Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical reinterventions
Endpoint domain: Adverse events/effects
Primary endpoint: SF-12 Mental Component Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-12 Physical Component Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ease of taking oral NaP solution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for bowel preparation in the future
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Nausea or vomiting incidence in PEG group
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in serum IL-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: THI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DASS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MAL Amount of Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivation to quit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in fat utilization during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in energy expenditure during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of neutrophils in psoriatic skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persistent bleeding after per-protocol hemostasis
Endpoint domain: Adverse events/effects
Primary endpoint: Attendance of treatment meals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvements in behavioral intervention outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of postoperative venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in lipid profiles (HDL2, LDL, VLDL, triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in carbohydrate metabolism (insulin, C-peptide, fasting glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from endoleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aneurysm sac diameter stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postprandial glucose excursion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Posttest scores for cough management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttest scores for fever management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fiberoptic view of the vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional circuit life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time required for the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of pain
Endpoint domain: Adverse events/effects
Primary endpoint: restoration status at the 30‐day clinical evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA2‐IR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite incidence of death and myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of PTC-NB for diagnosing PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of PTC-B for diagnosing PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between PTC-NB and PTC-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensation of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Local reactions within the first 7 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to effective ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IR-HOMA index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: A‐a O(2) gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: respiratory index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PaO(2)/FiO(2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in postinflammatory hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lightening of normal skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Practical evaluation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative pain
Endpoint domain: Adverse events/effects
Primary endpoint: Free Testosterone (free T) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: differential gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False-positive rate of diagnostic blocks
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in ISAC-measured specific IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in specific IgG4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eating disorder-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Eating disorder psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-month dropout rate
Endpoint domain: Mortality/survival
Primary endpoint: 6-month dropout rate
Endpoint domain: Mortality/survival
Primary endpoint: average treatment dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of diabetes mellitus (DM)
Endpoint domain: Mortality/survival
Primary endpoint: Lead levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic activated clotting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AT activity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cumulative postsurgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Running time to failure during Ex2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes